Product Details-
| Composition | Atorvastatin 10mg Fenofibrate 160mg |
|---|---|
| Dosage | TABLET |
| Packing Size | 10×10 |
| Packing | Alu-Alu |
Atvin F 10/160 is a highly effective lipid-lowering medication that combines two powerful agents: Atorvastatin (10mg) and Fenofibrate (160mg). This dual-action formulation is designed to manage dyslipidemia, hypercholesterolemia, and hypertriglyceridemia, offering comprehensive cardiovascular protection for patients at risk of heart disease, stroke, and other lipid-related complications. By addressing multiple lipid fractions in the bloodstream, Atvin F 10/160 stands as a reliable therapeutic choice for individuals who need aggressive lipid management and long-term cardiovascular health support.
This fixed-dose combination tablet provides convenience, efficacy, and safety, making it a preferred option for healthcare professionals and patients seeking to improve lipid profiles, prevent atherosclerosis, and reduce the risk of life-threatening cardiovascular events.
Atorvastatin: 10 mg
Fenofibrate: 160 mg
Dosage Form: Tablet
Packing: Blister packs (commonly 10×10 tablets per box, customizable as per packaging requirements).
Atorvastatin: HMG-CoA reductase inhibitor (Statin)
Fenofibrate: Fibric acid derivative (Fibrate class of drugs)
Together, these two agents create a synergistic effect that targets both LDL cholesterol (bad cholesterol) and triglycerides, while also improving HDL cholesterol (good cholesterol) levels.
Atorvastatin (10mg)
Atorvastatin works by inhibiting HMG-CoA reductase, an enzyme responsible for cholesterol synthesis in the liver. This results in reduced production of LDL cholesterol and triglycerides while modestly increasing HDL cholesterol levels. By lowering LDL-C, atorvastatin helps in preventing plaque buildup in arteries, thus reducing the risk of atherosclerosis and cardiovascular events.
Fenofibrate (160mg)
Fenofibrate activates peroxisome proliferator-activated receptor-alpha (PPAR-α), a nuclear receptor involved in lipid metabolism. This activation enhances the breakdown of triglycerides and increases the synthesis of apolipoproteins A-I and A-II, thereby improving HDL cholesterol levels. Fenofibrate is particularly effective in patients with high triglycerides, mixed dyslipidemia, or metabolic syndrome.
The combination therapy addresses both cholesterol and triglycerides, offering a comprehensive lipid management solution that a single agent alone may not provide.
Atvin F 10/160 is prescribed for:
Mixed dyslipidemia (elevated LDL-C, triglycerides, and low HDL-C)
Hypercholesterolemia (high cholesterol levels)
Hypertriglyceridemia (high triglyceride levels)
Cardiovascular risk reduction in patients with metabolic syndrome or type 2 diabetes
Atherosclerosis prevention and treatment
Secondary prevention in patients with a history of myocardial infarction, stroke, or other cardiovascular diseases
Dual Lipid Control
Atorvastatin primarily targets LDL-C, reducing “bad cholesterol” effectively.
Fenofibrate targets triglycerides, making this combination ideal for patients with both cholesterol and triglyceride abnormalities.
Improved HDL Levels
The combination therapy not only lowers harmful lipid levels but also improves HDL-C, offering protective cardiovascular benefits.
Atherosclerosis Prevention
Long-term use reduces plaque buildup in arteries, promoting healthy circulation and reducing risks of coronary artery disease.
Diabetes-Friendly Lipid Management
Patients with type 2 diabetes often experience mixed dyslipidemia; this dual combination is particularly beneficial for them.
Convenience of Single Tablet Therapy
A single tablet offers the combined benefit of two lipid-lowering agents, enhancing patient adherence and simplifying treatment.
The usual recommended dose is one tablet daily or as prescribed by a physician.
Tablets should be taken with water, preferably at the same time each day, with or without food.
Treatment should be accompanied by a low-fat, heart-healthy diet, regular exercise, and weight management strategies.
Dosage adjustments may be required based on lipid levels, age, liver and kidney function, and concurrent medications.
Patients should undergo baseline lipid profiling and liver function tests (LFTs) before initiating therapy.
Regular monitoring of liver enzymes, renal function, and creatine kinase (CK) levels is recommended, especially in those at risk of myopathy.
Pregnant and breastfeeding women should avoid this medication.
Caution is advised in patients with:
Active liver disease
Severe kidney impairment
Gallbladder disease
History of muscle disorders
While Atvin F 10/160 is generally well-tolerated, some patients may experience mild to moderate side effects such as:
Headache
Gastrointestinal discomfort (nausea, abdominal pain, diarrhea)
Muscle pain or weakness
Fatigue
Mild liver enzyme elevation
Rare but serious side effects include myopathy, rhabdomyolysis, and severe hepatic dysfunction. Immediate medical attention is required if unexplained muscle pain, dark urine, or severe weakness occurs.
Anticoagulants (e.g., warfarin): Fenofibrate may enhance anticoagulant effects.
Other lipid-lowering drugs: Caution when combined with other fibrates or high-dose statins.
Immunosuppressants: May increase the risk of kidney toxicity.
Oral hypoglycemics: Dose adjustments may be necessary for diabetic patients.
Atvin F 10/160 works best when combined with:
A low-cholesterol, low-fat diet rich in vegetables, fruits, and lean proteins
Regular physical activity (at least 150 minutes/week)
Weight management to reduce cardiovascular risk
Avoiding smoking and limiting alcohol intake
Comprehensive lipid management: Effectively addresses both cholesterol and triglyceride imbalances.
Proven cardiovascular protection: Reduces the risk of heart attacks, strokes, and atherosclerosis.
Trusted ingredients: Atorvastatin and fenofibrate are well-studied agents with strong clinical evidence supporting their efficacy.
Convenience: Fixed-dose combination in a single tablet improves compliance.
Store in a cool, dry place, away from direct sunlight and moisture.
Keep out of reach of children.
Do not use after the expiry date printed on the pack.
Atvin F 10/160 is a reliable, effective, and convenient solution for managing mixed lipid disorders and reducing cardiovascular risks. With its combination of Atorvastatin (10mg) and Fenofibrate (160mg), this tablet offers a dual approach to lipid control, helping patients achieve optimal cholesterol and triglyceride levels. When used as part of a comprehensive cardiovascular risk reduction plan—including a healthy diet, regular exercise, and lifestyle changes—Atvin F 10/160 can significantly improve overall heart health and quality of life.
This product is ideal for patients with high cardiovascular risk, diabetes-related dyslipidemia, or metabolic syndrome, ensuring holistic lipid management and long-term vascular protection. Healthcare professionals trust Atvin F 10/160 for its efficacy, safety, and patient compliance benefits.
